Zittoun R, Bouchard M, Facquet-Danis J, Percie-du-Sert M, Bousser J
Cancer. 1975 Feb;35(2):507-13. doi: 10.1002/1097-0142(197502)35:2<507::aid-cncr2820350232>3.0.co;2-a.
The prognostic value of the in vitro incorporation of labeled thymidine was evaluated in 53 cases of acute leukemia, by means of autoradiography and liquid scintillation (LS) count. A higher rate of incorporation before therapy with higher labeling index and LS- specific activity was observed in patients who later responded to chemotherapy with a complete remission. The in vitro depression of labeled thymidine incorporation after incubation with the two drugs selected for the induction therapy was more marked in those who responded to therapy than in the nonresponders. The in vitro incorporation of 3H-thymidine was also evaluated after 48 hours of chemotherapy ("vivo-vitro" test). A decrease of the incorporation was observed frequently in the responders. On the other hand, in the group of nonresponders, there was generally an increase of the incorporation measured by the liquid scintillation count, often contrasting with a decrease of the labeling index, and corresponding to a higher rate of intracellular incorporation. The prognostic value of these findings appears to be significant, as it allows the response to chemotherapy to be predicted, as well as allowing the selection of the various cytotoxic drugs.
通过放射自显影和液体闪烁（LS）计数，对53例急性白血病患者评估了标记胸苷体外掺入的预后价值。在后来对化疗有完全缓解反应的患者中，观察到治疗前掺入率较高，标记指数和LS比活性也较高。在与选定用于诱导治疗的两种药物孵育后，标记胸苷掺入的体外抑制在有反应者中比无反应者更明显。化疗48小时后也评估了3H-胸苷的体外掺入（“体内-体外”试验）。在有反应者中经常观察到掺入减少。另一方面，在无反应者组中，通过液体闪烁计数测量的掺入通常增加，常常与标记指数降低形成对比，并且对应于较高的细胞内掺入率。这些发现的预后价值似乎很显著，因为它可以预测对化疗的反应，也可以选择各种细胞毒性药物。
